<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<title>NCT04216563 ‚Äì Phase II Study of Dual Targeting of BCR-ABL1 by Adding the Allosteric Inhibitor ABL001 in Patients With Chronic Myeloid Leukemia (CML) and Minimal Residual Disease (MRD) While on Therapy With Tyrosine Kinase Inhibitors</title>
<link rel="stylesheet" href="../assets/styles.css"/>
</head><body><div class="container">
  <a href="../index.html">‚Üê Back to index</a>
  <h1>NCT04216563</h1>

  <div class="card">
    <div><strong>Title:</strong> Phase II Study of Dual Targeting of BCR-ABL1 by Adding the Allosteric Inhibitor ABL001 in Patients With Chronic Myeloid Leukemia (CML) and Minimal Residual Disease (MRD) While on Therapy With Tyrosine Kinase Inhibitors</div>
    <div class="meta"><strong>Year:</strong>  &nbsp; <strong>Authors:</strong> ‚Äî</div>
    <div class="meta"><a href="https://clinicaltrials.gov/study/NCT04216563" target="_blank" rel="noopener">Registry page</a></div>
  </div>

  <div class="card">
    <h3>Study Documents</h3>
    <ul class="list">
      <li>üìÑ <a href="https://cdn.clinicaltrials.gov/large-docs/63/NCT04216563/ICF_000.pdf" target="_blank" rel="noopener">Informed Consent Form</a></li>
    </ul>
  </div>

  <div class="card">
    <h3>Preview</h3>
    <iframe class="pdf-iframe" src="https://mozilla.github.io/pdf.js/web/viewer.html?file=https://cdn.clinicaltrials.gov/large-docs/63/NCT04216563/ICF_000.pdf"></iframe>
  </div>
</div></body></html>
